 A Norwegian syringe of fremanezumab | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | Calcitonin gene-related peptide (CGRP) α, β |
| Clinical data | |
| Trade names | Ajovy |
| Other names | TEV-48125, fremanezumab-vfrm |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618053 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Subcutaneous |
| Drug class | Calcitonin gene-related peptide antagonist |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 55–66% |
| Metabolism | Proteolysis |
| Elimination half-life | 30–31 days (estimated) |
| Excretion | Kidney |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6470H9952N1716O2016S46 |
| Molar mass | 145507.54 g·mol−1 |
Fremanezumab, sold under the brand name Ajovy, is a medication used to prevent migraines in adults.[8][6] It is given by injection under the skin.[8][6]
The most common side effect is pain and redness at the site of injection.[8] Other side effects include allergic reactions.[8] It is in the calcitonin gene-related peptide antagonist class of medications.[8]
It was approved for medical use in the United States in 2018,[8] the European Union in 2019,[7] the UK in 2020[4] and Argentina by September 2021.[9]
- ^ "Fremanezumab (Ajovy) Use During Pregnancy". Drugs.com. 3 October 2018. Retrieved 2 April 2020.
- ^ "Summary Basis of Decision (SBD) for Ajovy". Health Canada. Retrieved 29 May 2022.
- ^ "Ajovy Product information". Health Canada. Retrieved 31 May 2022.
- ^ a b "Fremanezumab". NICE - National Institute for Health and Care Excellence. Retrieved 25 June 2021.
- ^ "Ajovy (fremanezumab) 225 mg Pre-filled Syringe for Injection - Summary of Product Characteristics (SmPC)". (emc). Retrieved 27 September 2021.
- ^ a b c "Ajovy- fremanezumab-vfrm injection". DailyMed. U.S. National Library of Medicine. 5 February 2020. Retrieved 2 April 2020.
- ^ a b "Ajovy EPAR". European Medicines Agency (EMA). 29 January 2019. Retrieved 2 April 2020.
- ^ a b c d e f "Fremanezumab-vfrm Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 15 July 2019.
- ^ "Migraña: en qué consiste el nuevo tratamiento para esta enfermedad frecuente e incapacitante". 12 September 2021.